MA41375A - Anticorps igg bispécifiques et leurs procédés de préparation - Google Patents

Anticorps igg bispécifiques et leurs procédés de préparation

Info

Publication number
MA41375A
MA41375A MA041375A MA41375A MA41375A MA 41375 A MA41375 A MA 41375A MA 041375 A MA041375 A MA 041375A MA 41375 A MA41375 A MA 41375A MA 41375 A MA41375 A MA 41375A
Authority
MA
Morocco
Prior art keywords
igg antibodies
preparation processes
bispecific igg
bispecific
processes
Prior art date
Application number
MA041375A
Other languages
English (en)
Inventor
Hector Aldaz
Shane Atwell
Stephen J Demarest
Karen J Froning
Brian Arthur Kuhlman
Andrew Philip Leaver-Fay
Original Assignee
Lilly Co Eli
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ North Carolina Chapel Hill filed Critical Lilly Co Eli
Publication of MA41375A publication Critical patent/MA41375A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA041375A 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation MA41375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106494P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
MA41375A true MA41375A (fr) 2017-11-28

Family

ID=55358122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041375A MA41375A (fr) 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation

Country Status (5)

Country Link
US (2) US10774156B2 (fr)
EP (1) EP3247721B1 (fr)
ES (1) ES3031036T3 (fr)
MA (1) MA41375A (fr)
WO (1) WO2016118742A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821753T3 (es) * 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
EP3559048A1 (fr) 2016-12-22 2019-10-30 Eli Lilly and Company Procédés de production d'anticorps bispécifiques fabs et igg
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
EP3638699A1 (fr) 2017-06-16 2020-04-22 Eli Lilly and Company Composés d'anticorps modifiés et conjugués de ceux-ci
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
JP7657591B2 (ja) 2017-12-22 2025-04-07 アルジェニクス ビーブイ 二重特異性抗原結合コンストラクト
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
EP4599856A1 (fr) * 2019-02-18 2025-08-13 Lankenau Institute for Medical Research Matériaux de fermeture de plaie réduisant la cicatrice
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
EP4025598A1 (fr) 2019-09-06 2022-07-13 Eli Lilly and Company Protéines comprenant des domaines constants de récepteur de lymphocytes t
US20230242671A1 (en) 2020-03-25 2023-08-03 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
AU2022206475A1 (en) * 2021-01-11 2023-08-17 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2025042709A1 (fr) 2023-08-22 2025-02-27 Eli Lilly And Company Agents d'arni de protéine précurseur amyloïde (app)
WO2025085352A1 (fr) 2023-10-18 2025-04-24 Eli Lilly And Company Protéines de liaison au récepteur de la transferrine et leurs utilisations
TW202547525A (zh) 2024-02-02 2025-12-16 美商美國禮來大藥廠 SARM1 RNAi藥劑
WO2025166111A1 (fr) 2024-02-02 2025-08-07 Eli Lilly And Company Conjugués comportant une protéine de liaison au récepteur de la transferrine
WO2025224084A1 (fr) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Protéines comprenant des domaines constants du récepteur des lymphocytes t
WO2025250605A1 (fr) 2024-05-31 2025-12-04 Eli Lilly And Company Agents d'interférence d'arn acvr2a et acvr2b
US20250381284A1 (en) 2024-06-18 2025-12-18 Eli Lilly And Company PRNP RNAi AGENTS
WO2026072446A1 (fr) 2024-09-25 2026-04-02 Eli Lilly And Company Conjugués comprenant un lieur bis-mspt
WO2026080661A1 (fr) 2024-10-10 2026-04-16 Eli Lilly And Company Agents d'arn interférence de sod1

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573168A (en) 1896-12-15 silberman
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
EP2234641B1 (fr) * 2008-01-03 2015-08-19 Genmab A/S Anticorps monoclonaux anti-cd32b
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
EP2580243B1 (fr) * 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AU2012235758B2 (en) 2011-03-25 2015-05-07 IGI Therapeutics SA Hetero-dimeric immunoglobulins
CN103857700A (zh) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
PL2773671T3 (pl) * 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
WO2014154254A1 (fr) 2013-03-26 2014-10-02 Nokia Solutions And Networks Oy Méthode et appareil
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
WO2017055539A1 (fr) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps multispécifiques
EP3559048A1 (fr) * 2016-12-22 2019-10-30 Eli Lilly and Company Procédés de production d'anticorps bispécifiques fabs et igg
CN110382529B (zh) * 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies

Also Published As

Publication number Publication date
WO2016118742A1 (fr) 2016-07-28
US10774156B2 (en) 2020-09-15
US20210054103A1 (en) 2021-02-25
US20180009908A1 (en) 2018-01-11
ES3031036T3 (en) 2025-07-03
EP3247721A1 (fr) 2017-11-29
US11976136B2 (en) 2024-05-07
EP3247721B1 (fr) 2025-05-07

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
FR25C1022I2 (fr) Anticorps anti-pd-1
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3389699A4 (fr) Anticorps monoclonaux chimériques et humanisés anti-ctla4 humaine, et leurs utilisations
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
EP3334824A4 (fr) Anticorps anti-pd-1
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3507307A4 (fr) Anticorps bispécifiques
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3334763A4 (fr) Nouveaux anticorps anti-pd-1
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3363816A4 (fr) Anticorps anti-ox40 et son application
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
HRP20260436T1 (hr) Bispecifično protutijelo koje veže dll3 i cd3